Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

International Journal of Medical Sciences

Volumn 11, Issue 7, 2014, Pages 707-712

  Saito, Tomoko ^a   Chiba, Tetsuhiro ^a   Suzuki, Eiichiro ^b   Shinozaki, Masami ^b   Goto, Nobuaki ^a   Kanogawa, Naoya ^a   Motoyama, Tenyu ^a   Ogasawara, Sadahisa ^a   Ooka, Yoshihiko ^a   Tawada, Akinobu ^a   Kanda, Tatsuo ^a   Miyazaki, Masaru ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Numazu City Hospital   (Japan)

Author keywords

HCC; HCV; IFN; Recurrence; SVR

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; INDOCYANINE GREEN; INTERFERON;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; MIDDLE AGED; OUTCOME ASSESSMENT; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DISEASE FREE SURVIVAL; DRUG EFFECTS; HEPACIVIRUS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; VIROLOGY;

AGED; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 84900440590     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8764     Document Type: Article

References (28)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-917.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362: 1907-17.
3. Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1990; 87: 6547-9.
4. Simonetti RG, Cammà C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med. 1992; 116: 97-102.
5. Chemello L, Cavalletto L, Bernardinello E, et al. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol. 1995; 23(Suppl 2): 8-12.
6. Schvarcz R, Ando Y, Sönnerborg A, et al. Combination treatment with inter-feron alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol. 1995; 23(Suppl 2): 17-21.
7. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999; 29: 1124-30.
8. Sugiura N, Sakai Y, Ebara M, et al. Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C: clinical study of 26 cases. J Gastro-enterol Hepatol. 1996; 11: 535-9.
9. Ikeda K, Kobayashi M, Saitoh S, et al. Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients. Oncology. 2003; 65: 204-10.
10. Kubo S, Nishiguchi S, Hirohashi K, et al. Influence of previous interferon therapy on recurrence after resection of hepatitis c virus-related hepatocellular carcinoma. Jpn J Cancer Res. 2001; 92: 59-66.
11. Uenishi T, Kubo S, Hirohashi K, et al. Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2002; 24: 404-12.
12. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339: 1485-92.
13. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006; 4: 756-62.
14. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-36.
15. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-2.
16. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986; 315: 1575-8.
17. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005; 436: 967-72.
18. Kimura M, Haisa M, Uetsuka H, et al. TNF combined with IFN-alpha accelerates NF-kappaB-mediated apoptosis through enhancement of Fas expression in colon cancer cells. Cell Death Differ. 2003; 10: 718-28.
19. Herzer K, Hofmann TG, Teufel A, et al. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009; 69: 855-62.
20. Shigeno M, Nakao K, Ichikawa T, et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene. 2003; 22: 1653-62.
21. Hasegawa K, Kokudo N, Makuuchi M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol. 2013; 58: 724-9.
22. Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012; 57: 794-802.
23. Sugimachi K, Kinjo N, Ikebe M, et al. Significance of hepatic resection for hepatocellular carcinoma with sustained virological response to interferon therapy for chronic hepatitis C. Hepatol Res. 2013; 43: 605-9.
24. Sanefuji K, Kayashima H, Iguchi T, et al. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to inter-feron therapy for hepatitis C. J Surg Oncol. 2009; 99: 32-7.
25. Miyatake H, Kobayashi Y, Iwasaki Y, et al. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci. 2012; 57: 1092-101.
26. Sakae M, Kubo S, Takemura S, et al. Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2012; 43: 564-73.
27. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012; 366: 216-24.
28. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013; 58: 655-62.